Pre-made anti-CYP2D6 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research.

Cat:GM-Tg-hg-IP0015-Ab
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

$3,090.00

SKU GM-Tg-hg-IP0015-Ab Category

Description

Pre-made anti-CYP2D6 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CYP2D6 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. The target: CYP2D6, gene name: CYP2D6, also named as CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIID6, P450-DB1, P450C2D, P450DB1. This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is known to metabolize as many as 25% of commonly prescribed drugs. Its substrates include antidepressants, antipsychotics, analgesics and antitussives, beta adrenergic blocking agents, antiarrythmics and antiemetics. The gene is highly polymorphic in the human population; certain alleles result in the poor metabolizer phenotype, characterized by a decreased ability to metabolize the enzyme’s substrates. Some individuals with the poor metabolizer phenotype have no functional protein since they carry 2 null alleles whereas in other individuals the gene is absent. This gene can vary in copy number and individuals with the ultrarapid metabolizer phenotype can have 3 or more active copies of the gene. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2014].

Antigen Information

Catalog No.

GM-Tg-hg-IP0015-Ab-1,GM-Tg-hg-IP0015-Ab-2

Product Name

Anti-CYP2D6 monoclonal antibody

Format

mab

Target Name

CYP2D6

Gene ID

CYP2D6

Gene Name

CYP2D6

Gene Alias

CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIID6, P450-DB1, P450C2D, P450DB1

Protein Sub-location

Introcelluar Protein

Category of antibody

Therapeutics Target antibody

Derivation (species)

Mouse

Species Reactivity

Human(H)

CH1+2+3 Isotype (Receptor identification)

IgG

Type of Light Chain (VD-LC)

N/A

Expression platform

Mammalian Expression

Bioactivity validation

Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.

Tag

Fc

Products description

Pre-made anti-CYP2D6 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)

Purity

Purity: ≥95% (SDS-PAGE)

Application

Biological drug discovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Formulation

Lyophilized from sterile PBS, PH 7.4

Storage

Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.